

Fig. 1 GC-ECD chromatograms of the methylated derivative of a CB182 metabolite formed by liver microsomes of untreated (A), PB-treated (B) and MC-treated (C) rats

Table 1 Metabolism of CB182 by liver microsomes of rats, guinea pigs and humans and effects of CYP inducers on CB182 metabolism

	M-1 formed (pmol/hr/mg protein)		
Animal	Untreated	PB-treated	MC-treated
Rat	B.D.	1369 ± 162	N.D.
Guinea pig	18.7 ± 12.6	26.7 ± 11.7	17.7 ± 11.1
Human*	14.3 ± 2.0	-	-

N.D., not detected. B.D., below detection limit. -, not done.
Each value represents the mean ± S.D. of four animals.
*The value represents the mean ± S.D. of triplicate determination.

Table 2 Mass spectral data and retention times of the methylated derivative of a CB182 metabolite and its synthetic compound

Compound	Molecular weight	Mass spectral data (Relative abundance, %)						Retention time (min) in GC-MS
		$[M^+]$	$[M^+-15]$	$[M^+-35]$	$[M^+-43]$	$[M^+-50]$	$[M^+-70]$	
CB182	392	100	-	33	-	-	101	13.34
M-1	422	100	47	-	27	14	-	15.53
3'- CH_3O-CB182	422	100	45	-	29	18	-	15.53

-, not detected.



PCB182 **M-1**

Fig. 2 Postulated metabolic pathway of PCB182 in animal liver